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ABSTRACT
Cancer cachexia is the rapid, drastic loss of muscle mass associated with cancer and is
not reversible by conventional nutritional means (Brown et al., 2018; Brown et al., 2017). It
occurs in ~80% of cancer patients and is responsible for 20-40% of cancer-related deaths (Brown
et al., 2018; Brown et al., 2017). This condition leaves patients with fatigue, functional
impairment, reduced quality of life, and a decrease in survival rates. Cachexia occurs through an
imbalance between protein degradation and protein synthesis (Brown et al., 2018), which is
associated with inflammation and altered metabolic processes.
Several studies have investigated the effects of leucine on cancer cachexia, as it is known
for promoting muscle growth through the stimulation of anabolic signaling cascades while
inhibiting catabolism. These studies have all been conducted for a short period of time and have
shown promise for leucine as a treatment for cancer cachexia. However, one study found that
long-term (6 weeks) leucine supplementation increased epididymal fat mass while decreasing
muscle mass in rats fed a high-fat diet (Baum et al., 2016). In addition, Lee et al. (2019)
demonstrated exacerbated atrophy in tumor-bearing mice after 28 days of low-dose leucine
supplementation. Whether leucine is a viable long-term treatment for cancer cachexia requires
further investigation.
10 C57BL/6 (WT) mice and 7 APCMin/+ (APC) mice were used in this study and given
either tap water as a control or given 1.5% leucine-enriched water. Tissue harvest was conducted
at ~24 weeks of age for genetic and western blot analysis. There was a main effect of genotype
for decreased body and plantaris weight in APC mice compared to WT (p < 0.05), and a main
effect of leucine for lower plantaris weight/tibia length in APC mice (p < 0.05), which appeared
to be driven by the APCMin/+ genotype (p = 0.0841). Cyclin D1 mRNA abundance was ~2-fold

greater in APC mice compared to WT, although no difference was found with treatment. No
difference was found in MyoD or Myogenin mRNA abundance. Long-term leucine
supplementation appears to exacerbate atrophy, which appeared to be independent of protein
turnover or myogenesis disruption.
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Chapter 1: Introduction
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INTRODUCTION
Skeletal muscle is a highly plastic tissue, capable of maintaining the mass needed to
perform daily tasks. However, this ability is compromised when a body undergoes certain
pathological conditions such as tumor growth, resulting in a condition known as cancer cachexia.
Cancer cachexia occurs in about 50-85% of colorectal, pancreatic and lung cancer patients and is
characterized by a dramatic loss in fat and muscle tissue, negatively affecting mortality and
quality of life in cancer patients, and is inversely related to survival time (Aversa, et al., 2011;
Cruz et al, 2017; VanderVeen et al., 2017; Assi, Derbre, Lefeuvre-Orfila & Rebillard, 2016).
Consequently, it is one of the most devastating effects of cancer and has a direct correlation with
tumor development (the degree of which varies with the type of cancer) (Salomao & GomesMarcondes, 2012). This drastic loss in muscle tissue can contribute to a decline in functional
status and reduction in respiratory function (Aversa, et al., 2011). Not only does it affect the
patient’s mortality/survival time, it also impacts the patient’s response to chemotherapy and
increases susceptibility to chemotherapy-induced toxicity, as well as causing a higher incidence
of postoperative complications (Van Norren, et al., 2009).
The effect of cancer cachexia on skeletal muscle has been extensively studied, due to its
importance for health maintenance during aging, obesity, and many chronic diseases (Carson,
Hardee & VanderVeen, 2016; VanderVeen et al., 2017). However, there are considerable gaps in
our understanding of the roles of muscle properties that contribute to health and quality of life. In
addition to mass, skeletal muscle has several properties that impart health benefits to cancerridden organisms, including metabolic capacity and substrate utilization flexibility (Carson et al.,
2016). Skeletal muscle also has an endocrine function through the production and secretion of
myokines (Carson et al., 2016). Muscle health can in part be controlled through the regulation of
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protein turnover, which responds to a variety of stimuli. These stimuli work through intricate
cellular signaling pathways involving several organelles and structures, all of which can become
dysregulated in cancerous conditions.
Clearly, preventive measures are important and continue to be researched. However,
nutritional therapies have yet to prove effective and there are currently no approved treatments
for cancer cachexia due to the complexity and variability of the condition (Assi et al., 2016;
Brown et al., 2018; Carson et al., 2016). Many recent studies have investigated the complex
processes involved in cancer cachexia, as well as a myriad of potential treatments. One possible
treatment is leucine supplementation. This branched chain amino acid has been shown to
stimulate muscle protein synthesis through activation of the protein mTOR, as well as
attenuating protein degradation by inhibiting ubiquitin protein ligases (Baum, 2005; Baptista et
al, 2009; Junior et al., 2011).
The effects of leucine supplementation on cancer cachexia is not yet conclusive. Previous
research has shown that leucine supplementation is efficacious in maintaining muscle mass in
cancer cachexia, however these are short-term studies (12-21 days into treatment/cancer) (Cruz,
Oliveira, & Gomes-Marcondes, 2017; Gomes-Marcondes, Ventrucci, Toledo, Cury, & Cooper,
2003). These studies also showed that leucine supplementation attenuated protein degradation
and improved protein synthesis. In contrast, Viana et al (2016) showed leucine to have no effect
on body weight. In addition, Lee et al. (2019) demonstrated that muscle mass loss was
exacerbated in LLC tumor-bearing mice after 28 days of low-dose leucine supplementation.
The involvement of muscle mitochondria in wasting and metabolic quality is well
recognized (Brown et al., 2017; Carson, Hardee & VanderVeen, 2016; VanderVeen, Fix &
Carson, 2017). The role of mitochondria in cancer cachexia has therefore been investigated
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intensively during the past few years (Brown et al., 2017; Carson, Hardee & VanderVeen, 2016;
VanderVeen, Fix & Carson, 2017). The processes by which mitochondrial quality is maintained
are regulated by a variety of stimuli, including frequency of use, inflammation, and hormonal
signaling (Carson et al., 2016; Vanderveen et al., 2017). These processes include mitochondrial
biogenesis, dynamics, and mitophagy (Brown et al., 2017). Mitochondria function has a role in
ATP production, apoptosis, autophagy, and protein turnover (Carson et al., 2016). Many
processes involved in mitochondrial regulation are altered in cachectic muscle (Brown et al.,
2017). Brown et al. (2017) demonstrated that mitochondrial health is compromised before
measurable muscle wasting in a Lewis Lung Carcinoma (LLC) model of cancer cachexia,
beginning with increased reactive oxygen species (ROS) emission and followed by an impaired
mitochondrial network and respiratory function.
The current knowledge regarding the effects of leucine supplementation on mitochondrial
quality is limited. Mitochondrial content and biogenesis-related gene expression have both been
shown to increase with leucine supplementation (Liang, Curry, Brown & Zemmel, 2014). In
addition, D’Antona et al. (2010) demonstrated that antioxidant (SOD1, SOD2, and catalase)
protein and gene expression increased with branched-chain amino acid (BCAA) supplementation
as well, which could contribute to the modulation of ROS damage. Whether leucine
supplementation influences mitochondrial dynamics and/or mitophagy has yet to be determined,
and none of the processes related to mitochondrial quality and leucine supplementation has been
studied in relation to cancer cachexia.
In addition to mitochondrial quality, the balance in muscle protein turnover affects
muscle health, as well as mass. When protein synthesis is equal to protein degradation, mass
stays the same (Aversa et al. 2011; Haegens et al., 2012). In catabolic conditions, such as when

5
an organism has developed cancer, this balance shifts to increased protein degradation and
suppressed protein synthesis (Aversa et al., 2011; Brown et al., 2018). This state largely results
from activation of the ubiquitin proteasome and autophagy systems (White et al., 2011). Two
specific ubiquitin ligases have been identified as biomarkers of cachexia: MuRF1 and Atrogin-1
(Brown et al., 2018; Carson et al., 2010). Regarding anabolic pathways, cachexia-induced
reduction of MAPK, Akt, peIF2𝝰 and mTOR activities decreases protein synthesis (Aversa et al.,
2011, Viana & Gomes-Marcondes, 2015). As mentioned previously, leucine supplementation has
been shown to improve muscle mass through the stimulation of mTOR and the suppression of
some catabolic pathways, both in healthy and cachectic muscle (in short-term studies).
Therefore, long-term supplementation of this BCAA may prove to be beneficial for protein
turnover in tumor-bearing mice.
The purpose of this study is to investigate the effects of long-term leucine
supplementation on cancer cachexia. Of interest are the signaling pathways and resultant
outcomes of protein turnover and myogenesis. Based on the current literature, we hypothesize
that leucine supplementation will increase protein anabolism and decrease catabolism while
contributing to the impairment of myogenic regulation.
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CHAPTER 2: Literature Review
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There are two main model categories of cancer cachexia: 1) tumor injection and 2)
genetic models. The focus of this literature review will be to discuss the models of cancer
cachexia and the major components driving cancer cachexia: satellite cells, inflammation,
dysregulated protein turnover, and altered oxidative metabolism. There will be a discussion of
the pros and cons of the cachexia models and how each component muscle regeneration responds
within a healthy cell, within the confines of cancer cachexia, and to leucine-promoted signals.
Leucine will be discussed as an intervention for cancer cachexia as this topic is key to
understanding the complex nature of prevention and/or treatment of cancer cachexia.

Satellite Cells
The ability of skeletal muscle to regenerate is due in large part to satellite cells. These
cells are a population of heterogeneous, undifferentiated cells located between the basal lamina
and sarcolemma of muscle cells and account for 2-7% of myofiber nuclei in adults (Fu, Wang &
Hu, 2015). During hypertrophy or repair, satellite cells can fuse with existing muscle fibers for
nuclei donation. They have a substantial nuclear-to-cytoplasmic ratio, little organelle content,
and considerable amounts of heterochromatin.
In healthy, adult skeletal muscle, satellite cells remain in the GO phase in which cells are
inactive (Schultz, Gibson & Champion, 1978). Upon injury or mechanical stress satellite cells
migrate from their niche and proliferate, after which a proportion of them differentiate. Once
satellite cells enter the G1 phase of the cells cycle, they are referred to as myoblasts.
Upon differentiation satellite cells contribute to muscle mass in 2 ways: fusion to preexisting fibers and forming new fibers. When they fuse to existing fibers, they contribute to
myonuclear accretion, which allows for growth and replacement of damaged nuclei. The
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formation of new fibers is not common in skeletal muscle, but it does happen in smooth muscles,
such as in the uterus.

Satellite Cell Quiescence
The ability of satellite cells to repair and maintain muscle mass is dependent on a variety
of intrinsic and extrinsic signals. Myogenic regulatory factors (MRFs) have been shown to be
necessary for formation of muscle and the presence of myogenic cells in adult skeletal muscle.
These include Myogenin (also referred to as MRF4), MyoD (also known as myogenic
determination factor 1), and Myf5 (myogenic factor 5). Paired box proteins 3 and 7 (Pax3 and
Pax7) are also important in the regulation of myogenesis and are upstream of Myf5 and Myod in
the myogenic signaling pathway.
While in the quiescent phase, satellite cells express Pax7, Pax3, and possibly Myf5
(Cornelison & Wold, 1997). Myf5 has been found in ~90% of quiescent cells, indicating
myogenic commitment (Beauchamp et al., 2000). Pax 7 has a dual role of inducing myoblast
proliferation and delaying differentiation through regulation of MyoD. Its involvement in
expression of antiapoptotic factors has also been recognized. Pax3’s role is not well understood,
though what is known is that it is important in embryonic development. Myf 5 is thought to
regulate proliferation rate and homeostasis and is expressed at high levels in isolated satellite
cells; however, a small population of satellite cells do not express Myf5, for reasons that have yet
to be elucidated.
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Satellite Cells: From Activation to Proliferation
Upon activation of satellite cells, expression of Pax3, Pax7, and Myf5 is retained but
MyoD is now expressed as well, which is responsible for proliferation (Brown et al., 2018). Most
proliferating cells suppress Pax7 expression and up-regulate MyoD before differentiation;
however, a small population maintains Pax7 expression, repress MyoD and return to quiescence.
Proliferating satellite cells will begin to differentiate, during which all MRFs stop being
expressed, except for Myogenin which is up regulated. In fact, Myogenin is known to play a role
in the downregulation of Pax7 expression.
Satellite cells are not a homogenous population. Ten percent are stem cells and 90% are
progenitor cells. The stem cells express Pax7+/Myf5- and can divide asynchronously, producing
both stem and progenitor cells. This is due to miR-49, which is found in quiescent stem cells.
MiR-49 inhibits Dek, keeping the stem cell from becoming a progenitor cell. Progenitor cells
express Pax7+/Myf5+ and differentiate into muscle cells.
One of the key factors that releases the satellite cell from the GO phase into the G1 phase
is Cyclin D1. Cyclin D1 is regulated in part by hepatic growth factor as well as IL-6 (Serrano,
Baeza-Raja, Perduguero, Jardi & Munoz-Canoves, 2008). It is heavily expressed during
proliferation of the satellite cell and suppresses the differentiation function of MyoD (Skapek,
Rhee, Spicer & Lassar, 1995). Inflammatory cytokines and oxidative stress can initiate p38
activation which in turn activates MyoD transcription of Cyclin D1 inhibitors (Palacios et al,
2010).
Once the cells undergo multiple cycles of proliferation, terminal differentiation of the
satellite cells is initiated by Myogenin and Myf6/Mrf4 (Brown et al., 2018; Smith, Janney &
Allen, 1994).
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Labeling and Identifying Satellite Cells
Fluorescence microscopy is often used traditionally by tagging Pax7. However, solely
labeling Pax7 to confirm the state of the satellite cell is insufficient. By further labeling MyoD,
the status of the cell can be observed as quiescent, proliferating or differentiating. If the satellite
cell is quiescent or activated, it will not express MyoD.

Satellite Cells and Muscle Mass
Increases and decreases in mass are accompanied by alterations in muscle DNA content.
This suggests that the ratio of muscle DNA-to-cytoplasmic volume remains constant, which is
referred to as the myonuclear domain. Because myonuclei are post-mitotic, increases in muscle
mass must be dependent on satellite cells to maintain constant myonuclear domain. By
differentiating and fusing with muscle cells, satellite cells provide genetic machinery for
increases in protein synthesis.

Satellite Cells and Cancer Cachexia
While less appreciated than the more common acute injuries to skeletal muscle, muscle
atrophy is also related to muscle damage, a point that will be discussed in this section. Many
conditions of atrophy, including cancer, have been associated with the impairment of muscle
regeneration (Talbert & Guttridge, 2016). It has been shown that the sarcolemma of muscle
fibers become damaged due to factors released by tumors (Brown et al., 2018). There appears to
be a large increase in Pax7 protein expression in cachectic muscle, and He et al. (2016) showed
that depletion of Pax7 was sufficient to attenuate muscle wasting by rescuing the muscle
regeneration program. This demonstrated the contribution of Pax7 dysregulation to cancer
cachexia; however, the mechanism by which this occurs is still unknown.
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The ability of satellite cells to be activated does not seem to be the limiting factor in the
impairment of muscle regeneration. For various atrophy conditions including cancer, there is an
increase in muscle precursor cell number as muscle mass is lost. There are some who have
suggested that this may be a result of a fusion defect, preventing myoblasts from repairing the
damage (Talbert et al., 2016). He et al (2016) also showed that muscle precursor cells (MPCs)
isolated from healthy mice fuse into injured muscle of cancerous mice at a reduced frequency
compared to regenerating muscle in non-cancerous mice, suggesting that the environment of
cachectic muscle is not conducive to myoblast fusion. Strengthening this hypothesis, upon
removing the tumor these cells readily fused into muscle fibers. Another finding showed that
tumor factors can induce satellite cell apoptosis in vitro, which may lead to a decrease in overall
satellite cell number.
In addition to environmental factors, satellite cell protein expression seems to become
dysfunctional and thus affect regeneration. Muscles from cancerous mice show large increases in
Pax7 protein levels without increases in other myogenic transcription factor coding genes like
MyoD and Myogenin, which in healthy cells would be induced to regulate the completion of
proliferation and differentiation, respectively (Brown et al., 2018; He et al., 2016). An increase in
the ratio of Pax7 to MyoD can prevent or delay the expression of Myogenin and differentiation.
Thus, this dysregulation in Pax7/MyoD or Myogenin expression can lead to a block in muscle
regeneration by keeping cells from eventually fusing into muscle fibers.
One possible reason for this alteration in Pax7+ expression is the NF-𝜿B signaling
pathway. This signaling is activated by TNF-𝛂 in cachectic muscle fibers via the degradation of
NF-𝜿B’s inhibitor and has been shown to negatively regulate differentiation. He et al. (2016)
showed that while NF-𝜿B activity is absent in quiescent satellite cells, it is highly induced within
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other Pax7+ cells in tumor-bearing mice. They also found that deletion of NF-𝜿B signaling from
Pax7+ cells is sufficient to rescue muscle wasting. This was associated with increased fusion of
myoblasts into myofibers. Several inflammatory factors such as Tumor necrosis factor-α,
angiotensin II, and myostatin have been linked to cancer cachexia and have been associated with
NF-𝜿B activity (Li, Schwartz, Waddell, Holloway & Reid, 1998; Sriram et al., 2011).
Inflammation will be discussed in more detail later, including its potential role in cancer
cachexia.

Inflammation
This section will discuss, in depth, the role of inflammation for skeletal muscle
maintenance, the effect of leucine on inflammation, and current scientific observations of
inflammation in response to cancer and its subsequent role in cancer cachexia.
As previously discussed, skeletal muscle is a highly plastic tissue, capable of remarkable
adaptive changes in response to physiological stimuli. Inflammation plays an indirect role by
cleaning damaged tissue and releasing factors that, among other factors, activate protein
synthesis. In addition, proper inflammatory processes have a critical role in the guidance of
satellite cell function and thus, muscle regeneration (Tidball, 2005). Therefore, healthy
inflammation responses during skeletal muscle adaptations is vital for proper structural and
functional maintenance.
Leukocytes, immune cells recruited to tissues via inflammation, are activated by damage
to the tissue (Honda, Kimua & Rostami, 1990). Neutrophils will respond immediately to the site
of damage due to chemoattractants released by the activated macrophages (Brigitte et al., 2010).
These immune cells are vital for releasing pro-inflammatory cytokines such as TNFα, Il-6, IL-β
and IFN𝛾 and IL-10 (Puppa et al., 2014). During this time, an increase in activated, MyoD-
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expressing satellite cells is also observed with the possibility of IFN𝛾 as a candidate for key
regulation of the inflammatory response (Cheng, Nguyen, Fantuzzi & Koh, 2008). Specifically,
IFN𝛾 has been shown to bind to myogenic precursor cells, which initiates the JAK/STAT
pathway resulting in a proliferative, non-differentiating satellite cell. IL-6, a neutrophil- and
muscle-released cytokine, also activates the JAK/STAT pathway (Carson et al., 2010). This leads
to the subsequent activation and proliferation of satellite cells via regulation of cyclin D1
(Serrano et al., 2008).
In addition to IFN𝛾, TNFα has also been heavily implicated in its role for regulating
myogenesis. Macrophages and monocytes release the biggest percentage of TNFα in the muscle
microenvironment acutely following injury. TNFα plays a role in silencing Pax7 via MAPK
signaling, resulting in more prominent differentiation of the satellite cells. TNFα has also been
shown to increase differentiation of satellite cells by silencing the Notch-1 gene, which
suppresses MyoD and Myogenin expression. It has been shown to suppress Notch-1 signaling,
which suppresses MyoD and Myogenin expression thereby reducing differentiation and
increasing proliferation of satellite cells (Acharyya et al., 2010).
In regenerating muscle, IL-6 is produced by infiltrating macrophages and neutrophils
(Zhang et al., 2013), fibro-adipogenic progenitors (Joe et al., 2010), and satellite cells (Kami &
Senba, 1998). It has also been shown that human myoblasts release IL-6 in response to other
cytokines involved in the inflammatory process (Gallucci, Provenzano, Mazzarelli, Scuderi &
Bartoccioni, 1998). The release of IL-6 might trigger and control the actions of satellite cells
throughout the myogenic process, leading to proliferation, and possibly differentiation and fusion
(Gao et al., 2017). Similarly, myoblasts derived from IL-6 null mice have displayed reduced
differentiation and fusion capacities in vitro (Hoene, Runge, Haring, Schleicher & Weigert,
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2013). Thus, IL-6 appears to have a crucial role in myogenesis. While IL-6 is mostly considered
a pro-inflammatory cytokine, it also has been shown to have anti-inflammatory effects and to
improve systemic insulin action (Wunderlich et al., 2010), which has a role in skeletal muscle
protein synthesis.

Inflammation and Cancer
Clearly, inflammation is a key regulatory factor in skeletal muscle maintenance. Chronic
inflammation, however, can disturb protein turnover and oxidative metabolism, both of which
have been implicated in muscle wasting (Hardee et al., 2018; VanderVeen et al., 2017). Both
systemic and muscle inflammation have been studied for their regulation of muscle wasting in
cancer. The following section will discuss the current literature on the inflammatory factors in
response to cancer and their role in cancer cachexia.
As mentioned previously, one of the hallmarks of cachexia is elevated, chronic
inflammation (VanderVeen et al., 2017). Widely studied mediators of cancer-induced wasting
include pro-inflammatory cytokines such as Tumor Necrosis Factor α (TNFα), Interleukin-6 (IL6), transforming growth factor-β (TGF-β), IFN𝛾, and more (Cruz et al., 2017;VanderVeen, Fix &
Carson, 2017; VanderVeen, Hardee, Fix & Carson, 2018). These have been shown to be up
regulated in many cancer cachexia preclinical models (Cruz et al., 2017; Hardee et al., 2018;
VanderVeen, Fix & Carson, 2017). While these all seem to be associated with cancer cachexia,
IL-6 has been identified as a driver of cachexia through the interaction with cancer environments
(Carson & Baltgalvis, 2010; Hardee et al., 2018). Indeed, disrupted protein turnover and
metabolic homeostasis in the APCMin/+ mouse, a well-studied cancer cachexia model, is
dependent on elevated circulating IL-6 (Hardee et al., 2018; VanderVeen et al., 2018; Carson et
al., 2010). The effects of IL-6 on protein turnover seem to, at least in part, be due to a dose-
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dependent suppression of mTOR in APCMin/+ mice, as well as its effect on the expression of
lysosomal and ubiquitin-related mRNA and proteins (Hardee et al., 2018; White et al., 2011).
Muscle inflammatory signaling has also been investigated for the disruption of protein
turnover and metabolism in cancer cachexia (Narsale et al., 2016). Chronic activation of signal
transducer and activator of transcription 3 (STAT3), NF-𝜿B, p38, ERK1/2, and protein kinase B
(Akt) signaling in muscle have all been implicated in muscle wasting (Brown et al., 2018;
Hardee et al. 2018; Narsale et al., 2016; White et al., 2011).
Some interventions have been used to target inflammation specifically and have been
shown to modulate the inflammatory response to cachexia. For example, Narsale et al. (2016)
demonstrated that short-term administration of pyrrolidine dithiocarbamate, which has both antiinflammatory and antioxidant properties, rescued signaling pathways involved in turnover
regulation. In addition, Lundholm et al. (1994) showed that indomethacin, a cyclooxygenase
inhibitor, prolonged survival in cancer patients when compared to a placebo.

Protein Metabolism
Exercise is a common model of muscle damage used in laboratory experiments. The
current literature states that resistance exercise promotes muscle adaptation through gene
expression and elevated myofibrillar protein synthesis (Bell, Seguin, Parise, Baker & Phillips,
2015). Once genes are transcribed, they then become translated using tRNA. The ribosomal
complex is formed, and the peptide chain becomes elongated through the addition of amino acids
corresponding to the genetic code. Once the addition of amino acids is terminated, the peptide
chain is modified, during which the chain folds and side chains are added.
One major regulator of cell growth is the protein known as mTOR. Two major signaling
pathways lead to mTORC1 activation: Mapk/Erk as well as the PI3K/Akt pathways. mTOR has
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been implicated in the phosphorylation of eukaryotic translation initiation factor 4E-binding
protein 1 (4-EBP1) and ribosomal protein S6 kinase beta-1 (S6K1) (Haegens et al., 2012). There
are two types of mTOR: mTORC1, which is involved in protein synthesis and autophagy
repression, and mTORC2, which is involved in cell survival, metabolism, and cytoskeletal
organization. Several factors regulate mTOR activity including growth factors, hormones, amino
acids, energy availability, oxygen and stress.
Raptor and DEPTOR proteins are mTOR-associated binding proteins and seem to be
negatively correlated with fractional synthetic rate (Nilsson et al., 2013). DEPTOR is a
competitive inhibitor of mTOR and exhibits decreased expression in most cancer types. While
this would seem like a positive occurrence, stimulation of mTOR by leucine leads to degradation
of DEPTOR, which is necessary for activation of p70S6k, thus suppressing synthesis. REDD 1
also seems to negatively regulate rates of skeletal muscle protein synthesis by suppressing
mTOR. In one study, deficiency of REDD1 was shown to enhance signaling through mTORC1
following electrically induced contractions in a mice study (Gordon, Steiner, Lang, Jefferson &
Kimball, 2014).
For skeletal muscle to function and adapt, protein synthesis must be accompanied by
autophagy. In fact, deficiency in basal autophagy has been shown to induce muscle damage (Lira
et al., 2013). The process of autophagy facilitates clearance of dysfunctional, damaged, longlived or misfolded proteins and/or organelles through the formation of double-membrane
structures that form autophagosomes, which fuse with lysosomes to degrade materials
(VanderVeen et al., 2017; Lira et al., 2013). There are two types of autophagy in healthy
conditions. One is nonselective, which is induced by starvation, and selective, which involves the
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specific removal of aggregated proteins and damaged organelles and is required for quality
control.
The two major pathways that regulate autophagy are the ubiquitin proteasome and
autophagy-lysosome pathways. The ubiquitin proteasome pathway results in the degradation of
the greater part of proteins intracellularly and is responsible for regulated proteolysis,
progression of the cell cycle, regulation of transcription, and the presentation of antigens (Reid &
Li, 2001). Ubiquitin-activating enzyme (E1) first activates ubiquitin and is then shifted to the
ubiquitin carrier protein (E2) active site. Ubiquitin conjugating enzymes (E3 or E3 protein
ligase) are recognized by the bound E2, which allows the occurrence of conjugation reactions by
the formation of ubiquitin chain by attaching with each other and the protein substrate. The
proteasome can recognize a selected protein only after it is targeted by ubiquitin and then
processed into smaller peptides (Glickman & Ceichanover, 2002). During proteolysis, there are
three E3 protein ligases which are active in atrophy in muscle, namely E3α, MAFbx/atrogin-1
and MuRF1 (Bodine et al., 2001).

Protein Metabolism and Cancer Cachexia
Cancer cachexia has been shown to be partially mediated by altered protein metabolism.
Part of this is due to reduced muscle protein synthesis (Hardee et al., 2018; Brown et al., 2018).
For instance, IGF-1 expression and mTOR targets are suppressed in cancer cachexia (White et
al., 2011), while AMPK and Raptor phosphorylation are increased as cachexia progresses
(VanderVeen et al., 2017). However, Penna et al. (2010) demonstrated that muscle atrophy might
be independent of IGF-1 activity, and IGF-1 and insulin treatment have not been shown to
attenuate muscle wasting in cancer cachexia (Lazarus, Kambayashi, Lowry & Strassman, 1996).
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One anabolic protein, mTOR, has conflicting evidence in the literature. mTOR activity
has been shown to decrease with the development and progression of cachexia with APCMin/+
mice as well as mice bearing Lewis cell carcinoma (White et al., 2011; Puppa, Gao, Narsale &
Carson, 2014), mediated through activation of AMPK by IL-6 (Hardee et al., 2018). However,
mTORC1 inhibition has been reported to prevent muscle loss in cancer cachexia (Pigna et al.,
2016). In fact, pharmaceutical intervention with rapamycin restored autophagy in tumor-bearing
mice and prevented cachexia (Pigna et al., 2016). The results of another study suggested that
mTOR regulates the pro-cachectic factors IL-10 and IL-6 (Robert et al., 2012; Hatakeyama et al.,
2016). On the other hand, Baselga et al. (2012) found that treatment of cancer patients with
everolimus, an mTOR inhibitor, was associated with decreased weight and decreased appetite,
showing that mTOR inhibitors may worsen cachexia. Given this evidence, it is unclear whether
mTOR activation attenuates or contributes to cancer cachexia.
In addition to the dysregulation of anabolic pathways, autophagy has been found to be
activated in muscles of cachectic animals (Brown et al., 2018). This activation might be a
response to the inflammatory, nutritional and energy stresses induced by cancer growth to sustain
cell survival. Whether this response contributes to cachexia is still unclear, however.
IL-6, a cytokine known to be up-regulated in cancer environments, is associated with
both growth and atrophy (Gao et al., 2017). Under physiological conditions, IL-6 is an important
regulator of hypertrophy. Gao et al. (2017) demonstrated that IL-6 administration to C2C12
myotubes induced protein synthesis in a dose-dependent manner, in which the positive effects
seemed to diminish at higher concentrations of this cytokine. This protein synthesis was
accompanied by STAT3 activation, Akt-mTORC1 activation, and increased SOCS3 expression.
In another study, administration of IL-6 receptor antibodies has been shown to suppress the rate
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of cachexia, however it was not enough to reverse the condition (White et al., 2011). There has
also been some indication that IL-6 may have a role in mitophagy regulation (VanderVeen et al.,
2017).
As mentioned previously, several pro-inflammatory cytokines are significantly up
regulated in cancer patients. One such cytokine is TNF-α, which has multiple roles in muscle
physiology. It is known that TNF-α can increase satellite cell differentiation, however it is also
able to induce apoptotic cell death, cachectic condition and the inflammatory response. In
addition to reducing food intake, it has been shown that TNF-α has an important role in cachectic
muscle wasting through protein degradation (Li et al., 1998; Li & Reid, 2000). In fact, one study
showed that mice lacking the TNF-α receptor protein type 1 had decreased muscle wasting when
transplanted with Lewis lung carcinoma (Llovera et al., 1998). This effect is thought to be
mediated through activation of the ubiquitin proteasome pathway through NF-𝜿B signaling (Li
& Reid, 2000; Reid & Li, 2001).
The ubiquitin proteasome pathway has been shown to be stimulated in cachectic patients
(Khal, Wyke, Russell, Hine & Tisdale, 2005). Specifically, Atrogin-1/MAFbx and MuRF1 are
strongly up-regulated in several models of cancer cachexia (Brown et al., 2018; Carson et al.,
2010). Atrogin-1 promotes degradation of MyoD and eIF3-f, an activator of protein synthesis
(Csibi et al., 2010; Tintignac et al., 2005), while MuRF1 ubiquitinates several structural proteins
(Fielitz et al., 2007; Polge et al., 2011; Cohen et al., 2009).
One E3 ubiquitin ligase that found to play a role in cancer cachexia is TRAF6 (Narsale et
al., 2016), which is found to be induced in gastric cancer patients and is a potent inducer of
mitophagy (VanderVeen et al., 2017). TRAF6 knockout mice are resistant to muscle loss induced
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by cancer (Paul et al., 2010) and have reduced Atrogin-1 and MuRF1 expression. TRAF6 is also
necessary for optimal activation of JNK, AMPK, FoxO3 and NF-𝜿B (Paul et al., 2012).

Mitochondria
Mitochondria are organelles that are essential for a variety of processes such as oxidative
phosphorylation, ATP generation, autophagy, protein turnover, calcium signaling and apoptosis
(Carson et al., 2018, 18). Oxidative metabolism is directly tied to mitochondrial content and is
used in fiber type classification (Carson et al., 2016; VanderVeen et al., 2017).
The changes in mitochondrial health is partly achieved by the interplay between fusion
and fission (Carson et al., 2016). Fusion of mitochondrial membranes facilitates optimal ATP
production by enhancing mitochondrial networks and preventing mitochondrial DNA loss, while
fission contributes to the removal of damaged mitochondria. Fusion is regulated by fusion
proteins 1 and 2 (Mfn1/2) and optic atrophy protein 1 (OPA1) (Brown et al., 2017), the levels of
which decrease with the increase of IL-6 (Carson et al., 2016). Fission is regulated through
dynamin-related protein-1 (DRP1) and fission protein 1 (Fis1) expression (Carson et al., 2016).
Alongside the numerous mitochondrial processes, reactive oxygen species (ROS) are also
produced by these organelles. ROS are involved in the maintenance of many signaling pathways
(Bae, Oh, Rhee & Yoo, 2011). An overabundance of ROS can also lead to cellular and DNA
damage, protein oxidation and apoptosis (Brown et al., 2017; VanderVeen et al., 2017). To avoid
the buildup of damaged mitochondria, mitochondrial proteins damaged by ROS can be broken
down by specialized mitochondrial enzymes (Smith, Hartley, Cocheme & Muphy, 2012). If the
damage has not led to severe loss of function, mitochondria with damaged mitochondrial DNA
can fuse with healthier mitochondria to borrow and/or transfer missing components (Youle &
van der Bliek, 2012). Mitochondria that have accumulated greater damage and cannot maintain
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function, are subject to fission, followed by mitophagy (VanderVeen et al., 2017). Following this
process, mitochondria are replaced by active mitochondria produced in mitochondrial biogenesis.

Mitochondria in Cachectic Environments
Mitochondrial loss and dysfunction have been well characterized in many cachectic
conditions and has been tied to muscle fatigability, weakness, and dysregulated protein turnover
(Brown et al, 2017; Carson et al., 2016; VanderVeen et al., 2017). In fact, cachectic muscle
wasting has been shown to primarily occur in glycolytic muscle when compared to more
oxidative muscle (Brown et al., 2017; Carson et al., 2010).
Mitochondrial content and quality are regulated by mitochondrial biogenesis,
fission/fusion, and mitophagy. Part of the dysregulation of mitochondrial processes associated
with cachexia is the suppression of Mfn1/2 during the initial stages of this condition
(VanderVeen et al., 2017). In addition, there is a decrease in Opa1 and Drp1 content, as well as
an increase in Fis1 by the fourth week of tumor development (Brown et al., 2017). This suggests
that cancer-induced disruption of muscle oxidative capacity begins early in the process of
cachexia development and is accompanied by an increase in ROS production, along with an
increase in fragmented mitochondria (Brown et al. 2017; VanderVeen et al., 2017).
Removal of damaged mitochondria through autophagy is essential to the maintenance of
mitochondrial quality (Carson et al., 2016). This process is known as mitophagy and is linked to
mitochondrial dynamics and health (Carson et al., 2016). Indeed, deletion of the autophagic gene
Atg7 results in atrophy, mitochondrial abnormalities, and disorganization of sarcomeres (Carson
et al., 2016). In contribution to the mitochondrial dysregulation seen with cachexia, it has been
seen in APCMin/+ mice that expression of autophagy proteins does not increase until severe
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cachexia has developed (Carson et al., 2016); however, the mitophagy protein Bnip3 has been
seen to increase in APCMin/+ and LLC tumor-bearing mice (Brown et al, 2017).
The accumulation of dysfunctional mitochondria leads to the increase of ROS, which
may instigate the muscle wasting observed in cachectic mice as it has been shown to promote
catabolic functions such as the ubiquitin system (Li & Reid, 2000; Carson et al., 2016;
VanderVeen et al., 2017). There are three mechanisms by which ROS may contribute to the
increased rate of muscle wasting: (1) oxidative stress leads to calcium overload and activation of
calcium-dependent proteases such as calpain; (2) oxidative stress stimulates the 20S proteasome
system via the activation of caspase-3; (3) oxidative stress up-regulates expression of ubiquitin
E3 ligases through NF-𝜿B (Li & Reid, 2000). Further investigation is needed to determine
through which ROS-induced mechanism cancer might instigate muscle wasting.

Mitochondria and Leucine
Few studies have been done on the effect of leucine supplementation on mitochondrial
biogenesis, dynamics, and mitophagy in the context of cancer cachexia. It has been shown to
increase mitochondrial biogenesis through the increase in CoxIV mRNA (Liang 2014). Whether
leucine increases PGC1α remains unclear. It has been shown by Liang et al. (2014) that leucine
increases AMPK activity, which in turn activates PGC1α. In addition, several studies have
demonstrated leucine’s effect to increase PGC1α mRNA (Jiao, 2016; Junior, 2016; Liang 2014;
Lee, 2019), however a 6-week study on the effects of leucine on rats fed a high-fat diet found
that PGC1α decreased (Baum et al., 2016).
As far as we know there has not been any data regarding the effects of leucine on
mitochondrial dynamics, however we can begin to speculate the effect of leucine on
mitochondrial degradation, content, and quality. As most studies found that PGC1α increases
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with leucine supplementation, which besides being a regulatory factor of mitochondrial
biogenesis is also known to suppress the expression of atrogenes. Leucine is also known for its
inhibitory effect on proteasome, calpain and cathepsin-dependent degradative pathways. As
some of these processes are involved in mitophagy, it may be reasonable to hypothesize that
leucine supplementation decreases the rate of mitophagy. In combination with the upregulation
of mitochondrial biogenesis, this should lead to the increase of mitochondrial content. Indeed,
Liang et al. (2014) found that leucine supplementation increased this content in C2C12
myotubes. As for whether this increase in content is accompanied by an improvement in
mitochondrial quality is also a matter of speculation at this point. However, as leucine
supplementation has been associated with a decrease in ROS production. To support this
concept, it PCG1α is a known regulator of ROS defense systems, and PGC1α has been shown to
increase with leucine supplementation.

Strategies for Attenuation of Cachexia
Several studies have been conducted to prevent and/or treat cancer cachexia. For instance,
STAT3 and the myostatin pathway have been indicated as possible therapeutic targets for the
preservation of skeletal muscle in cachexia (Bonetto et al., 2012; Busquets et al., 2012). ActRII
inhibitors have shown to be a promising intervention for cancer cachexia (Hatakeyama et al.,
2016). IGF-1 administration has been studied by Costelli et al. (2006) as a possible method of
treatment, however it did not prevent cachexia.
Supplementation of leucine and HMB, a leucine metabolite, have also been studied. One
study on the effects of HMB for 24 days attenuated muscle and body weight loss on an 8-day AH130 injection model of cancer cachexia (Aversa et al., 2011). In studies performed by GomesMarcondes et al. (2003) and Cruz et al. (2017), 12 and 21 days, respectively, of leucine
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supplementation in tumor-bearing rats showed improvements in muscle mass and protein content;
however, Gomes-Marcondes also found that leucine supplementation accelerated tumor growth.
Peters et al. (2011), Salomao et al. (2012), and Viana et al. (2015) all found a similar result. One
of the few studies involving longer supplementation (6 weeks) with leucine showed that leucine
decreased muscle mass in rats fed a high-fat diet (Baum et al., 2016). In addition, Lee et al. (2019)
demonstrated that muscle mass loss was exacerbated in LLC tumor-bearing mice after 28 days of
low-dose leucine supplementation. Further investigations of long-term leucine supplementation
are needed to determine whether it is a viable treatment for cancer cachexia.

Leucine Supplementation
A plethora of data have shown the branched-chain amino acid leucine to initiate the
greatest anabolic signaling response through the mTORC1-p70S6K1 pathway (Anthony,
Anthony, Kimball & Jefforson, 2001; Haegens et al., 2012). However, this is not the only
mechanism through which leucine has been investigated regarding its role in muscle mass
regulation. Here we will discuss leucin supplementation as it pertains to satellite cells,
inflammation, and protein metabolism.

Satellite Cells with Leucine Supplementation
The research done on the effects of leucine supplementation on satellite cells is
promising. Wan et al. (2017) showed in a lipopolysaccharide model of muscle wasting that
leucine supplementation was associated with a decrease in NF-𝜿B activity, which shows promise
for the attenuation of Pax7 dysregulation. Indeed, Pereira et al. (2015) showed that leucine
supplementation in old rats is associated with an increase in satellite cell proliferation and a
decrease in the ratio of Pax7 to MyoD.
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Inflammation and Leucine
The investigation of the effect of leucine on inflammation is somewhat limited. One
study showed leucine to attenuate muscle protein degradation in tumor-bearing rats (Cruz et al.,
2017). However, this study only investigated the effects of leucine over a short time frame (21
days). This study found that leucine increased pro-inflammatory cytokines in tumor-bearing rats,
including TNFα, IL-6, and IFN𝛾, as well as the TNFα-IL10 ratio by day 14, however they all
returned to levels similar to day 7, with the exception of IFN-𝛄. For a short period of time, this
may help with the myogenic processes of satellite cells, as well as attenuate the progression of
the cancer itself. It is not known, however, whether the elevation of IFN-𝛄 would continue with
prolonged leucine supplementation, or whether this would prove to be beneficial or detrimental.

Protein Metabolism and Leucine
There is a lot of conflicting evidence regarding the effects of leucine on protein
metabolism. However, it is known to affect skeletal muscle anabolism through phosphorylation
of mTOR and its downstream targets (Haegens et al., 2012; Deldicque et al., 2008). Increased
leucine intake has also been shown to preserve lean mass and increase circulating levels of IGF-1
in calorie-restricted rats (Pedroso, Nishimura, de Matoso-Neto, Donato & Tirapequi, 2014). This
does not directly link IGF-1 with lean mass preservation; however, this could be evidence that
leucine activates mTOR through multiple pathways. This activation of mTOR may not be a
positive attribute, however, as leucine-stimulated mTOR leads to the degradation of DEPTOR,
which is necessary for the activation of the important synthetic factor p70S6k.
There is also conflicting evidence regarding the effects of leucine on glucose handling
and insulin sensitivity. Junior et al. (2015) found that leucine supplementation worsened glucose
homeostasis in sedentary and exercised mice. However, Baum et al. (2005) demonstrated that
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leucine, both alone and in conjunction with carbohydrate, had minimal effect on glucose uptake
in rats. The only difference both studies found in leucine’s effect on insulin signaling was a
blunted duration of insulin-induced PI 3-kinase activity when it was combined with carbohydrate
(Baum et al., 2005) and a decrease in insulin-stimulated AMPK phosphorylation (Junior et al.,
2011). Thus, while the effects of leucine on glucose sensitivity is yet under scrutiny, it does
appear to lessen the effects of insulin on pathways that regulate protein metabolism.
Leucine supplementation has also been shown to alleviate dexamethasone-suppressed
protein synthesis (Wang et al., 2016). In this study, the improvement in protein synthesis was
accompanied by increased phosphorylation of mTOR and decreased phosphorylation of AMPK,
a factor known to be up regulated with cancer cachexia.
A leucine-rich diet was shown to improve the cancer-induced down-regulation of the
mTOR signaling pathway, rescuing mTOR and p70 activation in tumor-bearing mice (Viana &
Gomes-Marcondes, 2015). The effects of leucine supplementation on SOCS3 has yet to be
studied with respect to skeletal muscle, however expression was decreased in adipose tissues of
rat fed a high-fat diet and didn’t change in the hypothalamus of lactating rats (Lopez, Sanchez,
Pico, Palou & Serra, 2010; Yuan, Han, Zhang, Xu & Qin, 2015).
In two separate studies, chronic leucine supplementation has been shown to decrease the
expression of TNF-α in rats on a high-fat diet (Jiao et al., 2016; Li et al., 2013). In addition, in
vitro incubation of muscle fibers showed a decrease in NF-𝜿B activity, through which it is
thought TNF-α activates the ubiquitin-proteasome pathway (Li et al, 2000). However, TorresLeal et al. (2011) found that leucine supplementation had no effect on TNF-α in rats that have
transitioned from a high-fat to low-fat diet.
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Two studies have shown that leucine significantly attenuates Atrogin-1 and MuRF-1 gene
expression in immobilized rats (Baptista et al., 2010; Baptista et al., 2013). Whether this is
beneficial or not remains to be seen. This inhibition of the ubiquitin pathway could attenuate the
imbalance between protein synthesis and degradation seen in cancer cachexia. However, it has
been suggested that mitochondrial quality is partly regulated by the ubiquitin system (Lehmann,
Udasin & Ciechanover, 2016). Impaired mitochondrial quality control has been found in cancer
cachexia, in which the accumulation of reactive oxygen species may contribute to the weight loss
found in cachexia (Brown et al., 2017). Thus, reducing the activation of the ubiquitin proteasome
pathway may lead to exacerbating cancer cachexia.

Models of Cachexia
The diverse models of cancer cachexia can be divided into two categories: injection and
genetic. Two injection models include Walker tumor injections and Lewis Lung Carcinoma
(LLC) injections. Both cell lines can be cultured and expanded in any lab and can quickly cause
the development of the cachectic phenotype (Pin et al., 2015). The LLC model is characterized
by a loss of muscle mass and strength and develops the cachectic state by about four weeks
(Brown et al., 2017). Using this model, mitochondrial health impairment has been demonstrated
well before the onset of measurable atrophy in cancer cachexia (Brown et al., 2017). One
drawback to consider is the ratio of tumor size to body weight. In implantation models, tumors
can be up to 10% of an animal’s body weight, which is a condition not normally found in human
cancer or cachexia. This could place confounding inflammatory and metabolic challenges on the
animal (Carson et al., 2010).
In contrast to injection cancer models, genetic models occur more gradually. One of the
most well-studied genetic models of cancer cachexia is the APCMin/+ mouse (Hardee et al., 2018;
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Brown et al., 2017; Carson et al., 2010; Narsale et al., 2016). This strain has a genetic mutation
in the adenomatous polyposis coli (APC) gene, which is a key tumor suppressor. Mutation of this
gene results in the spontaneous development of intestinal and colon tumors by four weeks of age
(Carson et al., 2010; Puppa et al., 2011). This model increases in weight similarly to the C57BL/
mouse until ~12 weeks of age, and then body weight decreases steadily between weeks ~12 and
~20 and leads to a 20-25% decrease in bodyweight (Puppa et al., 2011). This model requires
more time than injection modalities for the animals to reach the cachectic state, however it does
provide a valuable model that mimics human colorectal cancer and lacks anorexia (Baltgavis et
al., 2008).

Conclusion
Cancer cachexia is characterized by a drastic, rapid loss in body weight, fat and muscle
tissue, resulting in reduced quality of life and functionality (VanderVeen et al., 2017). This is
partly due to increased inflammation, protein breakdown, and impaired mitochondria (Brown et
al., 2017; VanderVeen et al., 2017). Interventions for treating/preventing cachexia have included,
among other treatments, STAT3, myostatin pathway, and ActRII inhibition, and leucine
supplementation. Thus far, full cachexia attenuation has not been achieved.
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AIMS
AIM 1: Examine how leucine supplementation affects protein turnover in cachectic mice.
Maintenance of muscle mass depends on the balance between protein synthesis and
protein degradation. The first aim of this study will be to see how protein turnover responds to
leucine supplementation in cachectic mice. Thus far, the response has yet to be completely
elucidated. By performing qRT-PCR and Western Blot we will be able to analyze signaling
pathways and mRNA expression related to protein synthesis and degradation.

AIM 2: Examine how leucine supplementation affects satellite cell dynamics.
The disruption of myogenesis during the progression of cancer cachexia is wellrecognized (Brown et al., 2018). The effects of long-term leucine supplementation on satellite
cell dynamics within the context of cancer cachexia has yet to be studied. To investigate the
regulation of satellite cell dynamics in response to leucine supplementation in this cachectic
model, we will use PCR to measure factors involved in activation and differentiation.
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ABSTRACT
Preservation of muscle mass is important for the maintenance of quality of life during
aging and a variety of diseases, including cancer. Cancer cachexia is characterized by rapid,
drastic loss in fat and muscle mass, and is irreversible by conventional nutritional means. It
occurs in ~80% of cancer patients and is responsible for 20-40% of cancer-related deaths and is
especially prevalent in cancers of the gastrointestinal system (Brown et al., 2018; Brown et al.,
2017; Puppa et al., 2011). This condition leaves patients with increased fatigue, loss of functional
independence, reduced quality of life, and a decrease in overall survival rates. Cachexia occurs
through an imbalance in skeletal muscle protein metabolism, with degradation rates overcoming
that of protein synthesis (Brown et al., 2018; Brown et al., 2017). These changes are often in
association with an increase in inflammation and an alteration in several metabolic processes.
Several studies have investigated the effects of leucine on cancer cachexia, as this
branched-chain amino acid is known for promoting muscle growth through the stimulation of the
anabolic signaling cascades while inhibiting catabolic processes. These studies have all been
conducted for a short period of time, with the longest being 24 days, and have shown promise for
leucine as a treatment for cancer cachexia. Whether leucine is viable as a long-term, chronic
treatment requires further investigation. 10 C57BL/6 (WT) mice and 7 APCMin/+ (APC) mice
were used in this study and given either tap water as a control or given 1.5% leucine-enriched
water. Tissue harvest was conducted at 20 weeks of age for gene expression and western blot
analysis. There was a main effect of genotype for lower body and plantaris weight in APC mice
when compared to WT (p < 0.05), and a main effect of leucine for a lower plantaris/tibia length
in APC mice (p < 0.05), which appeared to be driven by the APCMin/+ genotype (p = 0.0841).
Cyclin D1 mRNA abundance was ~2-fold greater in APC mice compared to WT, although no

34
difference was found with leucine supplementation. No difference was found in MyoD or
Myogenin mRNA abundance. Long-term chronic leucine supplementation appears to exacerbate
body weight and muscle mass loss. Our data suggest that this is independent of protein turnover
or myogenesis disruption.
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INTRODUCTION
In addition to mass, skeletal muscle has several properties that impart health benefits to
cancer-ridden organisms. Skeletal muscle quality is aligned with metabolic capacity and
substrate utilization flexibility (Carson, Hardee & VanderVeen, 2016). Skeletal muscle is heavily
involved in metabolic capacity and substrate utilization flexibility and serves an endocrine
function through the production and secretion of myokines (Carson et al., 2016). Muscle health
can in part be controlled through the regulation of protein turnover, which responds to a variety
of stimuli. These stimuli work through intricate cellular signaling pathways involving several
organelles and structures, all of which can become dysregulated in cancerous conditions.
Many types of cancer are accompanied by a rapid, drastic loss in skeletal muscle tissue,
which negatively affects mortality and quality of life in cancer patients. This condition, known as
cancer cachexia, occurs in about 50-85% of colorectal, pancreatic and lung cancer patients and is
inversely related to survival time (Aversa, et al., 2011; VanderVeen et al., 2017). Consequently,
it is one of the most devastating effects of cancer and has a direct correlation with tumor
development (the degree of which varies with the type of cancer) (Salomao & GomesMarcondes, 2012). This drastic loss in muscle tissue can contribute to a decline in functional
status and reduction in respiratory function (Aversa, et al., 2011). Not only does atrophy affect
the patient’s survival time, it also impacts the patient’s response to chemotherapy and increases
susceptibility to chemotherapy-induced toxicity, as well as decreasing the patient’s ability to
withstand infection (Van Norren, et al., 2009).
Clearly, preventive measures are important and thus continue to be researched. However,
nutritional therapies have yet to prove effective and there are currently no approved treatments
for cancer cachexia due to the complexity and variability of the condition (Assi et al., 2016;
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Brown et al., 2018). Many recent studies have investigated the complex processes involved in
cancer cachexia, as well as a myriad of potential treatments. However, the main obstacle to
treatment of this condition is that it is multifaceted. This condition is associated with anorexia,
altered oxidative metabolism, insulin resistance, systemic inflammation, and disrupted protein
turnover. Thus far no treatments have been found that address all contributing factors.
Some studies have shown promise, such as the study on ERK inhibition done by Penna et
al. (2010), however this was a short-term experiment (4-13 days) and it is unknown how chronic
inhibition of this protein would affect an organism with cancer. Studies targeting inflammation
have been inconclusive (Maddedu et al., 2012; Wu, Fernandez & Criswell, 2013), and there are
few studies involving oxidative metabolism. Narsale et al (2016) demonstrated that short-term
antioxidant treatment rescued signaling for protein turnover and increased body weight and
muscle mass in the APCMin/+ mouse. However, Assi et al. (2016) showed that antioxidant
treatment not only failed to attenuate the development of cachexia but also promoted tumor
growth and premature death. Lastly, the role of protein turnover in the attenuation of cancer
cachexia has also been studied. Specifically, the stimulation of skeletal muscle protein synthesis
has been of great interest, through the major protein mTOR.
The cell signaling protein mTOR is known to be stimulated by the Branched Chain
Amino Acid (BCAA) called leucine (Lee et al., 2019). Through inhibition of catabolism and the
stimulation of mTOR, leucine is well known for its anabolic and mass-saving effects on skeletal
muscle (Stipanuk, 2007). This BCAA has also been shown to prevent mitochondrial dysfunction
in high-fat diet-induced obese mice (Li et al., 2012). While leucine has been shown to attenuate
progression of cancer cachexia, these studies have only included short-term supplementation (12-
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21 days) with this amino acid (Baptista et al., 2010; Cruz, Oliveira & Gomes-Marcondes, 2017;
Peters et al., 2011).
To study cancer cachexia and its possible treatments, a variety of murine models are
used. The diverse models of cancer cachexia can be divided into two categories: injection and
genetic. One well-studied injection model is the LLC-induced cancer cachexia. This cell line can
be easily cultured and expanded in any lab, and it takes four weeks for the cachectic phenotype
to develop (Pin et al., 2015). The LLC model is characterized by a loss of muscle mass and
strength and can develop the cachectic state by four weeks (Brown et al., 2017). Using this
model, mitochondrial health impairment has been demonstrated well before the onset of
measurable muscle wasting in cancer cachexia (Brown et al., 2017).
In contrast to injection cancer models, genetic models occur more gradually. One of the
most well-studied genetic models of cancer cachexia is the APCMin/+ mouse (Hardee et al., 2018).
This strain has a genetic mutation in the adenomatous polyposis coli (APC) gene, which is a key
tumor suppressor. Mutation of this gene results in the spontaneous development of intestinal and
colon tumors (Carson et al., 2010; Puppa et al., 2011). This model requires more time than
injection modalities for the animals to begin developing tumors, and even longer for them to
develop the cachectic state. It does, however, mimic several characteristics found in human
colorectal cancer and lacks anorexia (Baltgavis et al., 2008).
While the importance of treating cancer cachexia is well known, a viable treatment has
yet to be found. Leucine supplementation has been particularly promising; however,
administration of this amino acid has been up to three weeks at most. Therefore, the purpose of
this study was to investigate the effect of long-term, chronic leucine supplementation on
APCMin/+ mice, which have a genetic mutation that leads to colorectal cancer and cachexia. We
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hypothesized that leucine would attenuate the development of cancer cachexia through the
stimulation of mTOR and the inhibition of catabolism. We demonstrate that chronic leucine
administration not only exacerbated the cachectic condition but seemed to shorten the lifespan of
tumor-bearing mice. These data suggest that leucine may not be a viable treatment option for
cancer patients, although further studies are required to determine if other administration
schedules have promise.

METHODS
Animals
10 male C57BL/6 (WT) and 10 APCMin/+ (APC) mice were used for this study. APC and
WT mice were randomly assigned to either no leucine (WTNL, n=5 and APCNL, n=5) or
leucine supplemented (WTL, n=5 and APCL=5) groups. Mice were group housed in the
University of Arkansas Central Laboratory Animal Facility. Animals were kept on a 12:12-hour
light-dark cycle in a climate-controlled room with ad libitum access to normal chow and water
throughout the study. Once weaned, animals in the NL group received normal water, while L
groups were given 1.5% leucine-rich water (Perry et al., 2016). Food and water mass
consumption were recorded weekly. Three APCL mice died before harvest, so n=2 was used for
this group and n=7 was used for the APC genotype group in our data collection and statistical
analysis. There was no difference in water consumption between NL and L (p=.9391) (Figure 1).
At twenty weeks of age, tissue harvest was conducted. All methods used in this study were
approved by the University of Arkansas Institutional Animal Care and Use Committee (IACUC).
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Tissue Harvest
Mice were anesthetized with a subcutaneous injection of a cocktail containing ketamine
hydrochloride (90 mg/kg body weight), xylaxine (3 mg/kg body weight), and acepromozine (1
mg/kg body weight). The plantaris was immediately flash frozen in liquid nitrogen and stored at
-80°C for protein and gene expression analysis. Following removal of the muscles, tibias of both
legs were extracted and measured via caliper. All collected tissue was stored in -80°C until
processed for analyses.

RNA Isolation, cDNA synthesis, and Quantitative Real-Time PCR
RNA was removed from the plantaris muscle using a Trizol reagent (Thermo Fisher
Scientific, Waltham, MA, USA). RNA was isolated using the Purelink mRNA minikit (Thermo
Fisher Scientific, Waltham, MA, USA). cDNA was reverse transcribed from 1 µg of total RNA
using the Superscript Vilo cDNA synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA).
Real-time PCR was performed, and results were analyzed using the StepOne Real-Time PCR
system (Thermo Fisher Scientific, Waltham, MA, USA). cDNA was amplified in a 25 µL
reaction containing appropriate probes and Taqman Gene Expression Mastermix (Thermo Fisher
Scientific). Samples were incubated at 95°C for 4 minutes, followed by 40 cycles of
denaturation, annealing and extension at 95°C, 55°C and 72°C, respectively, with fluorescence
measured at the end of the extension step each cycle. Fluorescent probes for 18s, IGF-1, MyoD,
Myogenin, Atrogin-1, MuRF-1, Cox IV and CCD1 were purchased from Applied Biosystems.
RT-qPCR measured cycle threshold (Ct) and the ΔCt value was calculated as the difference
between the Ct value and the 18s Ct value. Final quantification of gene expression was
calculated using the ΔΔCT method Ct = [ΔCt(calibrator) – ΔCt(sample)]. Relative
quantifications were then calculated as 2-ΔΔCt.
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Western Blot
Protein quantification for protein metabolism was probed and analyzed via Western Blot.
Plantaris muscle homogenate was fractioned in 6-15% SDS-polyacrylamide gels. Gels were then
transferred to low-fluorescing polyvinylidene difluoride (PVDF) membranes. Membranes were
stained with Ponceau S before blotting to verify equal loading of the gels. Membranes were
blocked in a 1:1 solution of containing Tris-buffered saline (TBS) with 0.1% Tween®20 (TBST)
for 2 hours. Primary antibodies for 4EBP-1 (pan) (#9644), p70S6K (pan) (#9202) and COX-IV
(#11967) were purchased from Cell Signaling (MA, US) and were diluted 1:1000 in 5% milk, in
TBST and incubated at 4°C overnight. Anti-mouse or anti-rabbit secondary antibodies (Cell
Signaling) were diluted at 1:20000 in 5% milk, in TBST and incubated at room temperature for
one hour. Fluorescence imaging was performed using the LI-COR Fc to visualize antibodyantigen interaction. Quantification of blotting images was performed through densitometry
analysis using Image Studio Lite v. 5.2 software. Ponceau stained membranes were digitally
scanned, and 45 kDa actin bands were quantified by densitometry to be used as a protein loading
correction factor for each lane.

Statistical Analyses
Data were calculated using Statistical Package for the Social Sciences (SPSS version
23.0, Armonk, NY). All results were reported as mean ± SEM. A priori comparisons between
WTNL and APCNL mice were conducted using Student’s t-tests. A two-way ANOVA was
performed to analyze main effects of genotype and treatment and any interactions between the
dependent variables. Where significance was detected, a Fisher’s LSD post-hoc analysis was
conducted. Statistical significance was determined if p ≤ 0.05.
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RESULTS

Phenotypic Data
As shown in Table 1, at the end of ~20 weeks there was a main effect of genotype for
APCMin/+ mice to have lower body mass than WT mice (p < 0.0001). There was no difference
between WT groups. Therefore, leucine treatment had no effect on WT mice body weights.
There was a trend for body mass to be lower in APCL when compared to APCNL (p = 0.0720).
While no interaction was found, there was a main effect of genotype for lower plantaris
weight/tibia length in APCMin/+ mice when compared to WT (Table 1, p < 0.0001) and a main
effect of leucine for lower plantaris weight/tibia length in APCL compared to APCNL (p < 0.05).
The plantaris weight/tibia length was similar between WTNL and WTL.

Polyp data
After ~20 weeks, the number of polyps of the APCMin/+ and WT mice was 46.57 ± 2.44
and 0.00 ± 0.00, respectively. The total number of polyps did not change between APCNL and
APCL (Figure 1A). There was no difference in the number of polyps larger than one millimeter.
However, there were more polyps under 1mm in the APCL group when compared to APCNL.

Markers of Myogenesis
There was a main effect of genotype for a lower Cyclin D1 mRNA abundance in
APCMin/+ mice compared to WT (Fig. 2A, p < 0.05). No difference was found in MyoD mRNA
abundance (Fig 2C). No difference was found in Myogenin mRNA abundance (Fig 2E, p <
0.05).
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Markers of Protein Turnover
IGF1 mRNA abundance had a trend to be lower in the APCNL group compared to
WTNL (Fig3F, p = 0.0616), although no difference in IGF-1 mRNA abundance was found with
leucine treatment. There was a trend toward higher p70 protein content in APCNL compared to
WTNL (Figure 3B, p = 0.0559), although no difference in protein content was found in P70 with
leucine treatment. There was a main effect of genotype for lower 4EBP1 protein abundance in
APCMin/+ mice compared to WT (Figure 3C, p < 0.05). An eight-fold increase of Atrogin-1
abundance in the APCNL group was found compared to WTNL, WTL and APCL groups (Fig
3D, p < 0.05). There was a main effect of genotype for there to be a greater MuRF- 1 mRNA
abundance in APCMin/+ mice compared to WT. There was a main effect of treatment for there to
be less MuRF-1 mRNA abundance in the APCL group compared to APCNL (Fig 3E, p < 0.05).

DISCUSSION
The purpose of this study was to investigate whether long-term supplementation of
leucine to APCMin/+ mice would attenuate the cachectic process associated with the cancer that
they develop. Not only did leucine fail to attenuate cancer cachexia, to our knowledge we are
among the first to provide evidence suggesting that chronic, long-term leucine treatment seems
to exacerbate the loss of body weight and muscle mass. This is in accordance with a finding by
Baum et al. (2016) in which rats fed a high-fat diet had lower muscle masses after being fed
leucine for 6 weeks, which is longer than any cachexia-related study has been performed to date.
It also confirms the findings of Lee et al. (2019), in which muscle mass loss was exacerbated in
LLC tumor-bearing mice after 28 days of low-dose leucine supplementation. Based on the
results, this effect does not seem to occur due to alterations in myogenesis or protein turnover.
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The process of myogenesis is normally triggered by damage to the muscle and then leads
to a series of processes involving satellite cell dynamics and overall skeletal muscle repair and,
in many cases, hypertrophy. Under cancerous conditions, however, there is some dysregulation
in satellite cell dynamics that impedes myogenesis and contributes to muscle wasting (Brown et
al., 2018). In this study, we found that genotype had a main effect to decrease Cyclin D1 mRNA
abundance, however there was no difference in Myogenin or MyoD. These findings are in
agreement with Brown et al. (2018), who also found in their 4-week time course study that
Cyclin D1 decreased with the progression of cachexia, and that while Myogenin and MyoD
decreased initially, they rebounded to basal levels by week 4.
Evidence regarding the effect of leucine on myogenesis has yet to be confirmed. Haegens
et al. (2012) found that leucine supplementation did nothing to affect myogenesis in C2C12
myotubes, and Perry et al. (2016) found no effect of leucine on Myogenin or MyoD in aged or
young mice following injury. It has been shown, however, to preserve Cyclin D1 protein
abundance in hindlimb suspension models (Bajotto, Sato, Kitaura & Shimomura, 2011), increase
MyoD in young and old rats (Pereira et al., 2015), and increase Myogenin in preterm rats (Dai,
Yu, Shen, Guo & Qiu, 2015). In contrast, our study showed no change in Cyclin D1, MyoD or
Myogenin mRNA abundance in WT or APCMin/+ mice. Han et al. (2007) suggested that the
stimulating effect of leucine on myogenesis may be through mTOR and its downstream targets.
Protein turnover has been demonstrated to be dysregulated during cancer cachexia. In
cachectic environments, IGF-1 expression has been shown to decrease (White et al., 2011). With
the increase in inflammation, which is common in cachectic environments, there is evidence to
support that mTOR signaling also decreases, along with mTOR targets p70 and 4EBP-1 (White,
Puppa, Gao, Sato, Welle & Carson, 2013; Hardee et al., 2018). In contrast, our data show no

44
change in IGF-1 expression and a trend for an increase in p70 protein abundance in cachectic
mice; however, there was a decrease in 4EBP-1 abundance. Further investigation is needed to
determine whether there is a change in phosphorylation of the latter two markers, however Baum
et al. (2016) found in one of the longest leucine studies to date that there was no effect of leucine
on 4EBP-1 or p70 after 6 weeks of supplementation in rats fed a high-fat diet.
In cancerous conditions, a leucine-rich diet was shown to increase protein synthesis by
improving the downregulation of the mTOR signaling pathway, rescuing mTOR and p70
activation in tumor-bearing mice (Viana & Gomes-Marcondes, 2014). A mixture of leucine and
valine has also been shown to increase the phosphorylation of 4EBP-1 in tumor-bearing mice
(Eley, Russell and Tisdale, 2007). Our data showed no change in IGF-1, p70 or 4EBP-1 with
leucine supplementation, which further corroborates the findings of Baum et al. (2016). That
said, further investigation is required to determine if these conditions would affect the
phosphorylation of p70 and/or 4EBP-1.
While markers for protein synthesis decrease in cachectic conditions, ubiquitin ligases
Atrogin-1 and MuRF-1 have been shown to increase (Brown et al., 2018). Our data presented a
confirmatory 8-fold increase of Atrogin in cachectic mice and a main effect for genotype to
increase MuRF-1, adding further support to these findings in the current literature.
In addition to stimulating protein synthesis pathways, leucine has also been shown to
attenuate Atrogin and MuRF-1 abundance in immobilized rats (Baptista et al., 2010; Baptista et
al., 2013). Confirmatory evidence showed that leucine supplementation attenuated Atrogin in
APCMin/+ mice and had a main effect for lowered MuRF-1 in APCMin/+ mice.
There are a couple of possible explanations for this anomaly. As Lee et al. (2019)
speculates, the combination of the stimulating effect both cancer and leucine independently have
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on energy expenditure may be exacerbating the overall energy imbalance. Nilsson et al. (2016)
point out that DEPTOR, a competitive inhibitor of mTOR, decreases in protein expression in
most cancer types. In addition, leucine-induced stimulation of mTOR leads to the degradation of
DEPTOR, which is necessary for the activation of p70. As p70 is important for the process of
protein synthesis, leucine may exacerbate the cancer-induced suppression of DEPTOR, resulting
in a decrease in p70 activity. One limitation to this study is the muscle used in this project. While
leucine has been shown to have a greater effect on the cross-sectional area of Type 1 fiber types,
the muscle used in this project was the plantaris, which is predominantly made up of fast-twitch
fibers (Perry et al., 2016).
While we did not investigate this process, another possible avenue to consider is
autophagy dysregulation. As Lee et al. (2019) demonstrated, STAT3, which is an inflammatory
marker, is suppressed with leucine supplementation in healthy mice. According to Puppa et al.
(2014), inhibition of STAT3 can decrease FOXO3a phosphorylation, which is a key regulator of
autophagy. This is further evidenced by the study conducted by Lee et al. (2019). Additionally,
mTOR, which is stimulated by leucine, can regulate the expression of autophagy genes (White et
al., 2011). Autophagy is necessary to remove dysfunctional mitochondria to prevent an increase
in ROS, which can induce atrophy if left unchecked (Assi et al., 2016; Carson et al., 2016).
Mitochondrial content and function are disrupted in cachectic environments, as evidenced by
Brown et al. (2017). Although leucine has been shown to increase mitochondrial biogenesis (Lee
et al., 2019), it is not yet known whether leucine improves overall quality and function. Bnip3, a
mitophagy marker, increases dramatically in cachectic mice due the increase in inflammation
(Brown et al., 2017; VanderVeen et al., 2017), while Zheng et al. (2019) demonstrated that
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leucine inhibits expression of this autophagic marker. This could lead to a buildup of
degenerated mitochondria, resulting in excessive ROS production (VanderVeen et al., 2017).
The purpose of this study was to investigate whether long-term supplementation of
leucine to APCMin/+ mice would attenuate the development of cachexia. Not only did it fail to
attenuate this disease, it seemed to exacerbate it. Further study is required to determine whether
this has anything to do with phosphorylation of mTOR’s downstream targets, and whether any
other physiological functions are negatively affected by long-term leucine supplementation. That
said, the present evidence would indicate that caution should be exercised when considering
prescribing leucine as a treatment for cancer patients.
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CHAPTER 5: Conclusion
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Conclusion
Based on the present study, it appears that long-term leucine supplementation not only
fails to attenuate cancer cachexia, but it seems to exacerbate skeletal muscle mass loss. This
would suggest that caution should be employed when considering leucine as a prescription for
cancer patients, as the result may be opposite of that intended. Further research is required to
determine the cause of this anomaly. Leucine seems to have some positive effect in short-term
studies, so it may also be beneficial to test different administration models.
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APPENDIX

Table Legends
Table 1. Bodyweight, plantaris weight, tibia length, and plantaris weight normalized to tibia
length at ~24 weeks. Values are means ± SEM. * Indicates a main effect of genotype. ** indicates
a main effect of leucine. Statistical significance we set at an alpha of p ≤ 0.05.

Figure Legends
Figure 1. Animal Data. (A) Average amount of water drunk per day. (B) Total number of polyps
in APCMin/+ mice treatment comparison. (c) Relative frequency of polyps by size at ~24 weeks.
* Signifies a trend (p = 0.10) for an increase in relative number of <1mm tumors with leucine
administration.
Figure 2. mRNA abundance of satellite cell dynamics-associated factors at ~24weeks. (A)
mRNA abundance of Cyclin D1. (B) T-test comparison of mRNA abundance of Cyclin D1. (C)
mRNA abundance of MyoD. (D) T-test comparison of mRNA abundance of MyoD. (E) mRNA
abundance of Myogenin. (F) T-test comparison of Myogenin mRNA abundance in APCNL and
WTNL. Main effects (ME) of genotype and/or injury appear on each graph when relevant.
p≤0.05.
Figure 3. mRNA abundance and protein content of protein synthetic factors p70 and 4E-BP-1 at
~24 weeks. (A) p70 protein content. (B) T-test comparison of p70 protein content in APCNL and
WTNL. (C) 4E-BP1 protein content. (D) T-test comparison of 4E-BP1 protein content in
APCNL and WTNL.
Figure 4. mRNA abundance of degradative factors Atrogin-1 and MuRF-1 at ~24wks. (A)
Atrogin-1 mRNA abundance. (B) T-test comparison of Atrogin-1 mRNA abundance in APCNL
and WTNL. (C) MuRF-1 mRNA abundance. (D) T-test comparison of MuRF-1 mRNA
abundance in APCNL and WTNL
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Figure 5. mRNA abundance of anabolic signal IGF-1 at ~24 weeks. (A) IGF-1 mRNA
abundance. (B) T-test comparison of IGF-1 mRNA abundance in APCNL and WTNL. Main
effects (ME) of genotype and/or injury appear on each graph when relevant. p ≤ 0.05.
Figure 6. mRNA abundance and protein content of Cox4. (A) Cox4 mRNA abundance. (B) Ttest comparison of Cox4 mRNA abundance in APCNL and WTNL. (C) Cox4 mRNA
abundance. Main effects (ME) of genotype and/or injury appear on each graph when relevant. p
≤ 0.05.
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Wild Type
APCMin/+

Table 1.

Group

Body Weight (g)

No Leu
Leu
No Leu
Leu

29.0 ± 1.0
29.1 ± 0.8
25.0 ± 0.6*
21.1 ± 0.8

Plantaris
(mg)

17.2 ± 0.7
16.7 ± 1.2
13.8 ± 0.9
9.3 ± 0.7

Tibia Length (mg)

Plantaris mass/
TL (mg/mm)

16.7 ± 0.1
16.8 ± 0.1
15.9 ± 0.2
16.5 ± 0.2

1.03 ± 0.3
1.00 ± 0.45
0.83 ± 0.05*
0.59 ± 0.04**

Relative frequency of polyps
by size (percentages)
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